Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.56 |
| ▸ | POLA1 | P09884 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13468595 | 1.00 | POLG (0.58) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL14853857 | 0.91 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL14929178 | 0.91 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL4454623 | 0.91 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL19537440 | 0.91 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL14929175 | 0.91 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL18561539 | 0.91 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL21006164 | 0.91 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL21007902 | 0.91 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB | |
| 2'-C-Methylcytidine Triphosphate SCHEMBL19537067 | 0.91 | P2RY2 (0.68) | POLGP2RY2P2RY4POLA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ADAR, SLC29A1, SLC28A1 | POLG 3031/4885P2RY2 94/4885P2RY4 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.